Product Name :
Saroglitazar Magnesium
Description:
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
CAS:
1639792-20-3
Molecular Weight:
901.42
Formula:
C50H56MgN2O8S2
Chemical Name:
magnesium(2+) bis((2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoate)
Smiles :
[Mg+2].CC1=CC=C(C2C=CC(=CC=2)SC)N1CCOC1C=CC(C[C@H](OCC)C([O-])=O)=CC=1.CC1=CC=C(C2C=CC(=CC=2)SC)N1CCOC1C=CC(C[C@H](OCC)C([O-])=O)=CC=1
InChiKey:
UJYFZCVPOSZDMK-YPPDDXJESA-L
InChi :
InChI=1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.|Product information|CAS Number: 1639792-20-3|Molecular Weight: 901.42|Formula: C50H56MgN2O8S2|Chemical Name: magnesium(2+) bis((2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoate)|Smiles: [Mg+2].{{Ritlecitinib} web|{Ritlecitinib} Stem Cell/Wnt|{Ritlecitinib} Purity & Documentation|{Ritlecitinib} References|{Ritlecitinib} custom synthesis|{Ritlecitinib} Autophagy} CC1=CC=C(C2C=CC(=CC=2)SC)N1CCOC1C=CC(C[C@H](OCC)C([O-])=O)=CC=1.CC1=CC=C(C2C=CC(=CC=2)SC)N1CCOC1C=CC(C[C@H](OCC)C([O-])=O)=CC=1|InChiKey: UJYFZCVPOSZDMK-YPPDDXJESA-L|InChi: InChI=1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (55.{{B-Raf IN 10} MedChemExpress|{B-Raf IN 10} MAPK/ERK Pathway|{B-Raf IN 10} Purity & Documentation|{B-Raf IN 10} In Vitro|{B-Raf IN 10} manufacturer|{B-Raf IN 10} Autophagy} 47 mM; Need ultrasonic).PMID:33201001 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes.|Products are for research use only. Not for human use.|
